Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development

Tracer Biotechnologies, a next-generation diagnostics company, today announced a multi-year project with AstraZeneca (LSE/STO/Nasdaq: AZN).

The agreement will allow AstraZeneca to use Tracer’s circulating tumor DNA (ctDNA) monitoring technology for clinical trials. Tracer has developed a proprietary platform for ctDNA detection based on digital polymerase chain reaction (PCR). The Tracer platform optimizes ctDNA detection, enabling cost-effective, accurate and scalable testing for patients as an alternative to radiographic imaging.

“We are entering a new era in oncology where patients will no longer have to wait for expensive and imprecise x-ray scans to assess treatment and disease progression,” said Mark Kaganovich, CEO of Tracer Biotechnologies. “We are proud to work with AstraZeneca to use frequent, accurate and cost-effective ctDNA measurement to detect minimal residual disease and monitor treatment response.”

About Tracer Biotechnologies

Tracer Biotechnologies is a state-of-the-art diagnostics company. The tracer is the only ultrasensitive ctDNA assay for molecular response monitoring. Combining tumor customization with dPCR allows Tracer to provide cost-effective testing for an unlimited number of study time points. Tracer testing is available for blood and urine.

For more information, please visit

See the source version on businesswire.com: https://www.businesswire.com/news/home/20241212366378/ro/

Contacts:

[email protected]